Navigation Links
Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
Date:11/5/2007

KENILWORTH, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) reported that the U.S. District Court for the District of Massachusetts has found no liability for Warrick Pharmaceuticals, its generic subsidiary, in a class action lawsuit involving several pharmaceutical companies and the setting of average wholesale prices (AWPs) for prescription products.

The Court, in a modification of its prior opinion, ruled that Warrick's AWPs had no effect on Medicare reimbursement and resulted in no damages to class plaintiffs. In June 2007, the Court had issued favorable rulings for the company and dismissed all claims relating to Schering-Plough's branded pharmaceutical products but found limited liability against Warrick with respect to one form of a generic product, albuterol sulfate solution, in the years 1998 and 1999. The Court's latest ruling in favor of the company reverses that finding of limited liability.

"As we move forward with building a company that can deliver sustainable high performance, we are gratified to put another issue from Schering-Plough's past behind us," said Fred Hassan, Schering-Plough chairman and CEO.

The company has consistently maintained that it has complied with all applicable laws and regulations governing pharmaceutical pricing and reimbursement in connection with reporting AWPs.

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physician
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
6. Haemacure Reports Third Quarter 2007 Results
7. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
8. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
9. MDS Reports Third Quarter 2007 Results
10. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
11. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...orporation Executive, Robert J. Reilly, Joins Aeth...on Inc.,( http://www.aethon.com ), the leading dev...n logistics, today announced that Robert J. Reilly...- Chief Financial Officer., Reilly, who was most ...esson Corporation,s Specialty Pharmacy Division, b...
(Date:7/25/2008)...25 /PRNewswire/ -- The Elekta Family of Companies ...t solutions at the 2008,American Association of Ph...trating how the joint forces of Elekta, IMPAC and ...planning and delivery solutions that,streamline th...for,patients, as well as enhance clinician efficie...
(Date:7/25/2008)...f., July 25 /PRNewswire/ -- AutoGenomics, Inc. tod...ement on Form S-1 with the,Securities and Exchange...c,offering of shares of its common stock. The numb... which are expected to be offered by,AutoGenomics,...not yet been,determined., J.P. Morgan Securities ...
(Date:7/25/2008)...ughest for those trying to drop pounds, study find...- Anyone who has avoided Monday morning weigh-ins ...ieter,s friend. , Now, researchers have some sc...s being their undoing: Most people do eat more on ...ht. , "Weekend indulgences can wreak havoc on w...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3
...r and death from cancer among Chinese women is ris...ai// Disease Prevention and Control Centre Friday....ghai urban area has almost doubled in 20 years and...ontracting the disease, the center reports. The l...
...rm Biocon Ltd Thursday announced the launch of ren...and reducing// the risk of such disease. As the l...ontinent, the company has set up a nephrology divi...odapt (Mycophenolate Mofeti), Tacrograf (Tacrolimu...
...a world-renowned California-based biomedical facil...ome up with a chemical// that would help prevent r...synthetic compound, called MTIP, blocks the action...-Releasing Factor (CRF), according to a joint anim...
...the food chain via the Bernard Matthews plant, whi...ird flu in early February this year. The Public ...ost 850 tons of turkey had to pass through the pla... had occurred in the interim period between outbre...
Other Medicine News:Health News:Biocon Unveils Renal Therapies for Kidney Disorders 2
(Date:7/24/2008)...re/ -- There are a record 301,new medicines being ...,report released here today during a briefing that...lnesses have on patients, their families,and soci...million American,adults. The briefing, led by the ...ca (PhRMA), featured Emmy Award-winning actor Joey...
(Date:7/24/2008)...-- MacroChem Corporation (OTC,Bulletin Board: MACM...ial,involving 37 patients who completed a 48-week,... study of EcoNail, a topical antifungal,lacquer fo...e composite,primary efficacy endpoint of the trial...(negative fungal culture and negative KOH) and cle...
(Date:7/23/2008)...armaceuticals (SPI) has filed,an Investigational N...testing of a proprietary formulation of ebselen fo...oss or ototoxicity. The oral capsule,containing eb...lung cancer,and head and neck cancer patients rece...second development program for SPI to enter clinic...
(Date:7/23/2008)...Code BioPharmaceutics, Inc.,an emerging biopharma...,results demonstrating the utility of their lead d...chronic blood disorder paroxysmal nocturnal,hemogl...nted at the XXII,International Complement Workshop...only treatment currently available for PNH patient...
Breaking Medicine Technology:More Than 300 New Medicines Being Developed for Mental Illnesses 2More Than 300 New Medicines Being Developed for Mental Illnesses 3More Than 300 New Medicines Being Developed for Mental Illnesses 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2MIT works toward novel therapeutic device 4265 1MIT works toward novel therapeutic device 4265 2MIT works toward novel therapeutic device 4265 3Endobronchial valve significantly improves emphysema 912 1Endobronchial valve significantly improves emphysema 912 2Kidney Care Community Voices Strong Support for Kidney Patients Right to Choose 4261 1Kidney Care Community Voices Strong Support for Kidney Patients Right to Choose 4261 2Kidney Care Community Voices Strong Support for Kidney Patients Right to Choose 4261 3New Study Shows Lower Costs Increased Consumer Engagement in Account Based Health Plans 4257 1New Study Shows Lower Costs Increased Consumer Engagement in Account Based Health Plans 4257 2
...NESS WIRE)--Jun 19, 2007 - Geron,Corporation (Nasd...,the scalable production, survival following engra...infarcted rats was presented,today for GRNCM1, the...therapeutic for heart failure, at the Internationa...eting in Cairns,Australia., The presentation was ...
...SS WIRE)--Jun 19, 2007 - Javelin,Pharmaceuticals (...ate Rylomine(TM) (intranasal morphine) successfull...e Pain Intensity Difference,(SPID) scores over 0-2...tal Phase 3 studies, patients with moderate-to-sev...ven 7.5 mg Rylomine every,hour as needed, 15 mg Ry...
Other Medicine Technology:Research Documents Scalable Production, Survival Following,Engraftment and Positive Impact on Cardiac Function in Infarcted,Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for,Heart Failure 2Research Documents Scalable Production, Survival Following,Engraftment and Positive Impact on Cardiac Function in Infarcted,Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for,Heart Failure 3Research Documents Scalable Production, Survival Following,Engraftment and Positive Impact on Cardiac Function in Infarcted,Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for,Heart Failure 4Research Documents Scalable Production, Survival Following,Engraftment and Positive Impact on Cardiac Function in Infarcted,Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for,Heart Failure 5Research Documents Scalable Production, Survival Following,Engraftment and Positive Impact on Cardiac Function in Infarcted,Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for,Heart Failure 6Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 2Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 3Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 4
... OPMI Vario/NC33 System, Carl Zeiss has successful...et. , ,The success of this instrument is by n...ct and stylish design. Maximum ergonomic convenien...n to be used with a surgical microscope, allowing ...
...g; Suction Punch Forceps provide superior tissue e.... Shutt® Suction Graspers offer an aggressive ...he jaws. Both feature a unique stress pin bufferin...In use, the stress pin buffering system applies in...
Leg holder for arthroscopy.
Osteoprep instruments provide an array of bone shaping devices especially suited for notchplasties.
Medicine Products: